country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

189 Results for "

APP holoprotein

" in MedChemExpress (MCE) Product Catalog:

Products (189)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

163

Mirdametinib

163 Publications Verification

Cat. No.: HY-10254

CAS No.: 391210-10-9

Purity: 99.95%

Synonyms: PD0325901; PD325901

Target:

MEK Autophagy Apoptosis

Research Areas:

Cancer

Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i ^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Takinib

33 Cited Publications

Cat. No.: HY-103490

CAS No.: 1111556-37-6

Purity: 99.41%

Synonyms: EDHS-206

Target:

MAP3K Apoptosis

Research Areas:

Infection Inflammation/Immunology Cancer

Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC₅₀=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (K_D(app) of 0.46 μM) .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

IXA4

13 Cited Publications

Cat. No.: HY-139214

CAS No.: 1185329-96-7

Purity: 98.83%

Target:

IRE1

Research Areas:

Neurological Disease

IXA4 is a highly selective, non-toxic IRE1/XBP1s activator. IXA4 activates IRE1/XBP1s signaling without globally activating the unfolded protein response (UPR) or other stress-responsive signaling pathways (e.g., the heat shock response or oxidative stress response). IXA4 reduces secretion of APP through IRE1 activation .

Compare